Literature DB >> 20129331

Surgical treatment of endometriosis in private practice: cohort study with mean follow-up of 3 years.

Jose Daniel Roman1.   

Abstract

STUDY
OBJECTIVE: To describe our experience with surgical treatment of endometriosis.
DESIGN: Observational cohort study (Canadian Task Force classification II-2).
SETTING: Private hospital. PATIENTS: One hundred sixty-three patients with histologically confirmed endometriosis who had completed a preoperative questionnaire, had available intraoperative findings and photographic documentation, and had been followed up to 6 years. INTERVENTION: Laparoscopic electrosurgical excision of endometriotic implants.
MEASUREMENTS AND MAIN RESULTS: Patients completed a visual analogue scale (VAS) for 6 components of endometriosis-related symptoms. The EuroQol Group EQ-5D questionnaire was used for evaluation of quality of life. Long-term follow up was performed using a questionnaire and review of patient medical records. Mean (SD; 95% confidence interval) patient age at surgery was 31.01 (8.5; 29.7-32.3) years. The primary symptom at initial consultation was dysmenorrhea in 94 patients (57.67%, nonmenstrual pelvic pain in 44 (27%), dyspareunia in 11 (6.75%), menorrhagia in 8 (4.9%), infertility in 4 (2.45%), and pelvic mass in 2 (1.23%). Thirty-three patients (20%) had undergone previous surgery because of endometriosis. At surgery, endometriosis was stage I in 50 patients (30.67%), stage II in 65 (39.88%), stage III in 23 (14.11%), and stage IV in 25 (15.34%). Other surgical procedures performed with the index surgery were cystoscopy in 48 patients (29.45%), laparoscopic ovarian cystectomy in 24 (14.72%), laparoscopic hysterectomy in 15 (9.2%), laparoscopic appendectomy in 9 (5.5%), sigmoidoscopy in 6 (3.68%), laparoscopic oophorectomy in 6 (3.68%), extensive laparoscopic adhesiolysis in 5 (3.07%) bowel resection in 2 (1.25%), laparoscopic myomectomy in 1 (0.61%), and bladder resection in 1 (0.61%). Surgery proceeded to laparotomy in 6 patients (3.68%). Major surgical complications included bowel perforation, severe pelvic pain 1 week after laparoscopic excision, and temporary numbness of the right side of the perineum in 1 patient each. Minor postoperative complications included urinary tract infection in 3 patients and port site infections that resolved with oral antibiotic therapy in 2 patients. Follow-up was 37.82 (20.09; 34.74-40.92) months. Surgical excision of endometriosis had a positive effect on endometriosis-related symptoms. Four pain scores were reduced, with statistically significant differences (p<.001 and p<.05): dysmenorrhea, pelvic pain not related to menstruation, dyspareunia, and dyschezia. The positive effect of surgical excision on patient quality of life was demonstrated by a statistically significant difference on the EQ-5D index (p<.001) and the EQ-5D VAS (p<.001). Thirty-two (20%) patients underwent a second procedure after the index surgery. Endometriosis stage affects the probability of requiring further surgery because of recurrent symptoms. There was evidence of endometriosis at histologic analysis in only 13 (40.62%) patients who required further surgery.
CONCLUSION: Laparoscopic excision of endometriosis significantly reduces pain and improves quality of life as measured by both the EQ-5D index and the EQ-5D VAS, with a low complication rate. Copyright (c) 2010 AAGL. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20129331     DOI: 10.1016/j.jmig.2009.09.019

Source DB:  PubMed          Journal:  J Minim Invasive Gynecol        ISSN: 1553-4650            Impact factor:   4.137


  9 in total

1.  Visualization of endometriosis: comparative study of 3-dimensional robotic and 2-dimensional laparoscopic endoscopes.

Authors:  Cindy Mosbrucker; Anita Somani; John Dulemba
Journal:  J Robot Surg       Date:  2017-03-02

2.  Quality of Life Assessment Using EuroQOL EQ-5D Questionnaire in Patients with Deep Infiltrating Endometriosis: The Relation with Symptoms and Locations.

Authors:  C Touboul; P Amate; M Ballester; M Bazot; A Fauconnier; E Daraï
Journal:  Int J Chronic Dis       Date:  2013-07-24

3.  Hormone treatment as first line therapy is safe and relieves pelvic pain in women with bowel endometriosis.

Authors:  Marina Paula Andres; Renata Franco Pimentel Mendes; Camila Hernandes; Sérgio Eduardo Alonso Araújo; Sérgio Podgaec
Journal:  Einstein (Sao Paulo)       Date:  2019-05-02

4.  Systematic review of quality of life measures in patients with endometriosis.

Authors:  Nicolas Bourdel; Pauline Chauvet; Valentina Billone; Giannis Douridas; Arnaud Fauconnier; Laurent Gerbaud; Michel Canis
Journal:  PLoS One       Date:  2019-01-10       Impact factor: 3.240

5.  Intestinal endometriotic nodules with a length greater than 2.25 cm and affecting more than 27% of the circumference are more likely to undergo segmental resection, rather than linear nodulectomy.

Authors:  Helizabet Abdalla-Ribeiro; Marina Miyuki Maekawa; Raquel Ferreira Lima; Ana Luisa Alencar de Nicola; Francisco Cesar Martins Rodrigues; Paulo Ayroza Ribeiro
Journal:  PLoS One       Date:  2021-04-15       Impact factor: 3.240

6.  Health-related quality of life in women with endometriosis: a systematic review.

Authors:  Shuang-Zheng Jia; Jin-Hua Leng; Jing-Hua Shi; Peng-Ran Sun; Jing-He Lang
Journal:  J Ovarian Res       Date:  2012-10-18       Impact factor: 4.234

7.  Is a bowel resection necessary for deep endometriosis with rectovaginal or colorectal involvement?

Authors:  Pedro Acién; Clara Núñez; Francisco Quereda; Irene Velasco; Marta Valiente; Virginia Vidal
Journal:  Int J Womens Health       Date:  2013-07-29

Review 8.  Diagnosis, management, and long-term outcomes of rectovaginal endometriosis.

Authors:  Nash S Moawad; Andrea Caplin
Journal:  Int J Womens Health       Date:  2013-11-08

9.  Treatment efficacy for pain complaints in women with endometriosis of the lesser pelvis after laparoscopic electroablation vs. CO2 laser ablation.

Authors:  Ewa Posadzka; Robert Jach; Kazimierz Pityński; Marcin Jacek Jablonski
Journal:  Lasers Med Sci       Date:  2014-07-23       Impact factor: 3.161

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.